RVPH
Reviva Pharmaceuticals Holdings Inc.
NASDAQ: RVPH · HEALTHCARE · BIOTECHNOLOGY
$0.87
+0.43% today
Updated 2026-04-30
Market cap
$11.68M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-5.48
Dividend yield
—
52W range
$1 – $23
Volume
1.6M
Reviva Pharmaceuticals Holdings Inc. (RVPH) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $724740.00 | — | — | — | — | — |
| Gross profit | — | — | $-724740.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $946301.00 | $195744.00 | $295150.00 | $4.85M | $18.95M | $31.42M | $22.91M | $11.71T |
| SG&A | $175579.00 | $181116.00 | $2.14M | $5.25M | $5.36M | $8.08M | $7.89M | $8.49T |
| Operating income | $-1.12M | $-376860.00 | $-2.43M | $-10.10M | $-24.31M | $-39.50M | $-30.80M | $-20.20T |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-1.12M | $-376014.00 | $-2.33M | $-8.52M | $-24.11M | $-39.21M | $-29.88M | $-20.20T |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-1.12M | $-376860.00 | $-2.43M | $-10.10M | $-24.31M | $-78.71M | $-60.68M | — |
| Interest expense | $557675.00 | $469373.00 | $1.45M | $2414.00 | $182802.00 | $33725.00 | $18497.00 | $13.40B |
| Income tax | $800.00 | $800.00 | $800.00 | $6004.00 | $20777.00 | $16949.00 | $19514.00 | — |
| Effective tax rate | -0.0% | -0.1% | -0.0% | -0.1% | -0.1% | -0.0% | -0.1% | 0.0% |
| Net income | $-1.68M | $-846832.00 | $-3.78M | $-8.52M | $-24.34M | $-39.26M | $-29.92M | $-19.86T |
| Net income growth (YoY) | — | +49.6% | -346.8% | -125.2% | -185.6% | -61.3% | +23.8% | -66395947.5% |
| Profit margin | — | — | — | — | — | — | — | — |